Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.
Experts are calling for a protected drugs list to stop shortages that could impact the chance of survival for childhood cancer patients.
Could combining the oncolytic viral therapy TVEC with other therapies enhance the immunotherapy’s efficacy, allowing more patients to benefit?
Although patients with CML may not be eligible for TKI discontinuation based on transcript alone, the type of transcript seen may have some implications for loss of treatment remission.
Researchers identified 15 genes that they said independently predict the survival outcome of patients with kidney renal papillary cell carcinoma.
Researchers provide further proof that CRISPR can augment cancer treatment in the lab, but many barriers remain before clinical trials can be conducted in patients.
